SCHEMBL16005254

SCHEMBL16005254

COc1cc(NCc2cc(F)ccc2O)ccc1C(=O)OC1CC2CCC1(C)C2(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
XBP1 P17861 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
MAPK1 P28482 2/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
SHBG P04278 1/20 0.44
EGFR P00533 4/20 0.43
ELANE P08246 2/20 0.42
CYP19A1 P11511 2/20 0.39
NOX4 Q9NPH5 1/20 0.38
NTRK1 P04629 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
SCN9A Q15858 2/20 0.37
CYP2C19 P33261 1/20 0.37
HSP90AA1 P07900 1/20 0.37
CKS1B P61024 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16005306 0.93 MAPT (0.50) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16005302 0.92 EGFR (0.48) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16005523 0.91 MAPT (0.46) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16005384 0.91 MAPT (0.46) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16146022 0.90 MAPT (0.44) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16146375 0.88 MAPT (0.44) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16005211 0.84 MAPT (0.49) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16005567 0.84 MAPT (0.49) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16005162 0.83 MAPT (0.45) MAPTKDM4EGAAXBP1NPSR1
SCHEMBL16004984 0.83 MAPT (0.47) MAPTKDM4EGAAXBP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2774914-B1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF UNIV NANJING MEDICAL (CN) 2017-12-06 EP claimed
US-20140303248-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF Neurodawn Pharmaceutical Co., Ltd. (CN) 2014-10-09 US claimed
EP-2774914-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF Nanjing Medical University (CN) 2014-09-10 EP claimed
US-20140303248-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF Neurodawn Pharmaceutical Co., Ltd. (CN) 2014-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303248-A1 N-BENZYLANILINE DERIVATIVE AND USES THEREOF NLN, INA, TRPV1 MAPT 887/4885KDM4E 2946/4885GAA 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.